← FDA DRUG APPROVALS

FDA ANDA · ANDA062926

RUBEX

Sponsor: BRISTOL MYERS SQUIBB

APPLICATION
ANDA062926
TYPE
ANDA
ORIGINAL APPROVAL
1989-04-13
LATEST ACTION
2001-05-24
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

RUBEXDiscontinued
DOXORUBICIN HYDROCHLORIDE 50MG/VIAL · INJECTABLE · INJECTION
RUBEXDiscontinued
DOXORUBICIN HYDROCHLORIDE 100MG/VIAL · INJECTABLE · INJECTION
RUBEXDiscontinued
DOXORUBICIN HYDROCHLORIDE 10MG/VIAL · INJECTABLE · INJECTION

Approval history

2001-05-24Labeling · Supplement 7AP
2000-11-02Manufacturing (CMC) · Supplement 8AP
2000-05-11Manufacturing (CMC) · Supplement 5AP
1999-08-24Labeling · Supplement 4AP
1998-12-01Labeling · Supplement 3AP
1997-07-11Labeling · Supplement 2AP
1996-07-24Labeling · Supplement 1AP
1989-04-13OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →